2,296 Quest Diagnostics Incorporated $DGX Shares Bought by Net Worth Advisory Group

Posted by Francis Steltz on Oct 20th, 2026

Net Worth Advisory Group increased its position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 47.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,129 shares of the medical research company’s stock after acquiring an additional 2,296 shares during the period. Net Worth Advisory Group’s holdings in Quest Diagnostics were worth $1,662,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Focused Alpha LLC grew its holdings in Quest Diagnostics by 50.6% in the 3rd quarter. Focused Alpha LLC now owns 4,509 shares of the medical research company’s stock worth $1,051,000 after buying an additional 1,515 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Quest Diagnostics by 47.0% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 23,513 shares of the medical research company’s stock valued at $5,480,000 after acquiring an additional 7,514 shares in the last quarter. CWA Asset Management Group LLC acquired a new position in Quest Diagnostics during the 3rd quarter worth $4,121,000. Greg Jennings LLC bought a new position in shares of Quest Diagnostics in the third quarter worth $764,000. Finally, Clark Wealth Partners grew its stake in shares of Quest Diagnostics by 14,182.4% in the third quarter. Clark Wealth Partners now owns 2,428 shares of the medical research company’s stock worth $566,000 after purchasing an additional 2,411 shares in the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Quest Diagnostics

In other news, SVP Mark Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the transaction, the senior vice president owned 10,335 shares of the company’s stock, valued at $2,430,585.30. The trade was a 13.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. Davis sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the completion of the sale, the chief executive officer owned 122,423 shares in the company, valued at $29,714,510.56. The trade was a 7.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 34,277 shares of company stock valued at $8,316,493 in the last quarter. Insiders own 0.88% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on DGX. JPMorgan Chase & Co. raised their price target on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Barclays upped their price objective on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Robert W. Baird boosted their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Mizuho upped their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Finally, Wall Street Zen raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and an average target price of $238.23.

Read Our Latest Research Report on DGX

Quest Diagnostics Stock Down 0.0%

DGX opened at $234.92 on Tuesday. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $248.84. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. The stock’s fifty day moving average is $237.35 and its 200-day moving average is $215.75. The company has a market capitalization of $25.93 billion, a PE ratio of 22.09, a P/E/G ratio of 2.13 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, equities analysts predict that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be given a dividend of $0.86 per share. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. Quest Diagnostics’s dividend payout ratio (DPR) is 36.52%.

Quest Diagnostics Company Profile

(Free Report)

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.